TITLE

Earnings Roundup

PUB. DATE
May 2013
SOURCE
BioWorld Today;5/13/2013, Vol. 24 Issue 91, p2
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports on earnings of biotechnology company Salix Pharmaceutical Ltd. of Raleigh, North Carolina for the first quarter of 2013 which includes sales of its antibiotic Xifaxan (rifaximin).
ACCESSION #
87593102

 

Related Articles

  • Salix Pharmaceuticals. Investor's Business Daily // Investors Business Daily;10/8/2014, pA02 

    The article reports that Salix Pharmaceuticals Ltd. closed down 2.4% as of October 10, 2014.

  • Salix Pharmaceuticals Reports 3Q2011 Results and Raises 2011 Guidance.  // Biomedical Market Newsletter;11/16/2011, Vol. 21, p440 

    The article focuses on the third quarter 2011 financial report of Salix Pharmaceuticals Ltd. In Raleigh, North Carolina. It mentions that the company has a total product revenue of 146.2 million dollars, which shows an 81 percent increase from the same period in 2010. According to Salix...

  • Earnings Roundup.  // BioWorld Today;3/ 4/2013, Vol. 24 Issue 41, p2 

    The article offers news briefs related to the corporate profits of biopharmaceutical companies in the U.S. for the fourth quarter of 2012. Medivation Inc. posted a corporate profit of 57.4 million dollars. Salix Pharmaceuticals Ltd. reported a generally accepted accounting principles (GAAP) net...

  • Earnings Roundup.  // BioWorld Today;8/10/2012, Vol. 23 Issue 155, p2 

    This article reports on the net earnings posted by U.S. drug manufacturers Avanir Pharmaceuticals Inc., Salix Pharmaceuticals Ltd. and ViroPharma Inc., for the second quarter of 2012.

  • Earnings Roundup.  // MondayMorning;8/15/2011, Vol. 19 Issue 30, p17 

    The article offers information on the financial performance of several pharmaceutical companies of the U.S. in 2011. Salix Pharmaceuticals Ltd. reported net income of 19.2 million dollars in the second quarter and its total product revenue increased to 133.2 million dollars. CareFusion Corp.'s...

  • Go with the gut. MILDENBERG, DAVID; MARTIN, CATHY // Business North Carolina;Aug2014, Vol. 34 Issue 8, p42 

    The article discusses the business growth of drug developer, Salix Pharmaceuticals, Ltd., as of August 2014. Topics mentioned include an increase in the company's stocks due to increased profits and sales of its treatments for gastrointestinal diseases, its rank in the publication "Business...

  • Valeant Sales Miss, Q1 Earnings Beat With Allergan Eyed. AMY REEVES // Investors Business Daily;5/ 9/2014, pA01 

    The article offers news briefs on sales in 2014. Drug manufacturer Salix Pharmaceuticals Ltd. reports decline in its sales in the year. Drugmaker Valeant Pharmaceuticals International Inc. reports 35% increase in its earnings per share with 77% increase in its sales. Eye health product supplier...

  • Salix Pharmaceuticals Reports 1Q2011 Results.  // Biomedical Market Newsletter;5/9/2011, p414 

    The article focuses on the financial and operating results of Salix Pharmaceuticals Ltd. during the first quarter ended March 31, 2011. The company reported a total product revenue of 105.9 million dollars for the first quarter, a 140% increase from the same quarter of 2010 and a net income of...

  • Salix Pharmaceuticals Gives Investors Another Chance. KEN HOOVER // Investors Business Daily;8/ 5/2014, pB01 

    The article offers information on a three-weeks-tight pattern that might be formed in American pharmaceurtical company, Salix Pharmaceuticals Ltd. The $2.7 billion acquisition made by the company to Irish subsidiary of Italy-based Cosmo Pharmaceuticals SpA is mentioned. The company's improved...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics